Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00613379 · ClinicalTrials.gov registry record · Phase 2
PRO 140 by IV Administration in Adults With HIV-1 Infection
A Phase 2 study, sponsored by CytoDyn.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00613379 is a Phase 2 study that has completed, run by CytoDyn. The registered enrollment target is 30 participants.
The verdict
NCT00613379, a Phase 2 study, has completed, sponsored by CytoDyn.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is: 1. To assess and characterize the PK and PD of PRO 140 administered IV 2. To assess the antiviral activity of PRO 140 3. To assess the safety and tolerability of PRO 140
Interventions
- DRUG Placebo
- DRUG PRO 140
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2007-12 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00613379
The ClinicalTrials.gov registry entry for NCT00613379 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytoDyn, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00613379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00613379 about?
NCT00613379 is a clinical study titled "PRO 140 by IV Administration in Adults With HIV-1 Infection". The purpose of this study is: 1. To assess and characterize the PK and PD of PRO 140 administered IV 2. To assess the antiviral activity of PRO 140 3. To assess the safety and tolerability of PRO 140
What is the current status of trial NCT00613379?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2007-12. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00613379?
The interventions under investigation include: Placebo (DRUG), PRO 140 (DRUG).
Who is sponsoring clinical trial NCT00613379?
This trial is sponsored by CytoDyn, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.